行情

INNT

INNT

INNOVATE BIOPHARMACEUTICALS INC
NASDAQ

实时行情|Nasdaq Last Sale

0.7460
+0.0158
+2.16%
盘后: 0.7500 +0.004 +0.54% 16:58 12/11 EST
开盘
0.7400
昨收
0.7303
最高
0.7496
最低
0.7303
成交量
8.12万
成交额
--
52周最高
4.320
52周最低
0.7100
市值
191.66万
市盈率(TTM)
-1.1189
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INNT 新闻

  • 美农场破产量飙升24%创6年新高 农业危机“在路上”?
  • 第一财经.12/03 09:53
  • 资金流向复盘 | 南下资金今日净流入港股超28亿港元
  • 华盛通.12/03 09:50
  • 瑞银:欧央行利率会议中性看待欧元 明年有望徐徐上涨
  • 新浪财经综合.12/03 09:46
  • 巴西“黑五”电商收入32亿雷亚尔 285万人“剁手”
  • 中国新闻网.12/03 09:39

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

INNT 简况

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.
展开

Webull提供Innovate Biopharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。